Falconer to Share Strategic Insights on Scaling Innovation, Securing Critical Infrastructure, and Accelerating Capital Growth in the AI Security Sector Falconer to Share Strategic Insights on Scaling Innovation, Securing Critical Infrastructure, and Accelerating Capital Growth in the AI Security Sector

NEW YORK, NY / ACCESS Newswire / May 13, 2025 / If you suffered a loss on your Zynex, Inc. (NASDAQ:ZYXI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/zynex-inc-lawsuit-submission-form?prid=148256&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / May 13, 2025 / If you suffered a loss on your Solaris Energy Infrastructure, Inc. (NYSE:SEI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/solaris-energy-infrastructure-inc-lawsuit-submission-form?prid=148257&wire=1 or contact Joseph E. Levi, Esq.

Key Highlights Alps Alpine selects Jivaro Pro to improve designer productivity and safeguard time-to-market goals Jivaro Pro is a unique stand-alone tool offering advanced parasitic reduction to dramatically accelerate SPICE simulations by up to 15x for designs down to 3nm Jivaro Pro seamlessly fits into existing flows and is simulation-and extraction-tool agnostic, providing designers with flexibility and usability SANTA CLARA, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Silvaco Group, Inc. (“Silvaco”) (NASDAQ: SVCO), a leading provider of TCAD, EDA software, and SIP solutions that enable semiconductor design and digital twin modeling through AI software and innovation, today announced that Alps …

NEW YORK, NY / ACCESS Newswire / May 13, 2025 / If you suffered a loss on your West Pharmaceutical Services, Inc. (NYSE:WST) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/west-pharmaceutical-services-inc-lawsuit-submission-form?prid=148258&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / May 13, 2025 / If you suffered a loss on your Zenas BioPharma, Inc. (NASDAQ:ZBIO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/zenas-biopharma-inc-lawsuit-submission-form?prid=148259&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / May 13, 2025 / If you suffered a loss on your Civitas Resources, Inc. (NYSE:CIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/civitas-resources-lawsuit-submission-form?prid=148250&wire=1 or contact Joseph E. Levi, Esq.

LOS ANGELES, May 13, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today agreed on terms for an exclusive collaboration agreement with Amsterdam University Medical Center (“Amsterdam UMC”) to jointly evaluate and develop blood platelet RNA diagnostics. This partnership marks an important step forward in the clinical validation and advancement of a promising new approach to disease detection and monitoring.

NEW YORK, NY / ACCESS Newswire / May 13, 2025 / If you suffered a loss on your Solaris Energy Infrastructure, Inc. (NYSE:SEI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/solaris-energy-infrastructure-inc-lawsuit-submission-form?prid=148257&wire=1 or contact Joseph E. Levi, Esq.

XI'AN, China, May 13, 2025 (GLOBE NEWSWIRE) -- BON Natural Life Limited (Nasdaq: BON) (“BON” or the “Company”), a leading provider of bio-ingredient solutions for the natural health and personal care sectors, today announced the groundbreaking launch of its sleep health product series. Developed using the proprietary “Glucoraphanin-Myrosinase” delivery system (patent-pending), the Company intends for this product to dramatically enhance the bio-activity (the extent to which something is absorbed and utilized by the body) of glucoraphanin, a vital bio-active compound in broccoli and will be launched under the Company's owned brand.

NEW YORK, NY / ACCESS Newswire / May 13, 2025 / If you suffered a loss on your West Pharmaceutical Services, Inc. (NYSE:WST) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/west-pharmaceutical-services-inc-lawsuit-submission-form?prid=148258&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / May 13, 2025 / If you suffered a loss on your Zenas BioPharma, Inc. (NASDAQ:ZBIO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/zenas-biopharma-inc-lawsuit-submission-form?prid=148259&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / May 13, 2025 / If you suffered a loss on your Civitas Resources, Inc. (NYSE:CIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/civitas-resources-lawsuit-submission-form?prid=148250&wire=1 or contact Joseph E. Levi, Esq.

LOS ANGELES, May 13, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today agreed on terms for an exclusive collaboration agreement with Amsterdam University Medical Center (“Amsterdam UMC”) to jointly evaluate and develop blood platelet RNA diagnostics. This partnership marks an important step forward in the clinical validation and advancement of a promising new approach to disease detection and monitoring.

MELVILLE, N.Y., May 13, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to announce that preliminary 26-, 52- and 104-week blinded preliminary data from the first 15 patients with chronic lumbar disc disease (“cLDD”) enrolled in the ongoing Phase 2 clinical trial of BRTX-100 was recently presented by Francisco Silva, Vice President of Research and Development, at the International Society for Cell & Gene Therapy (“ISCT”) 2025 Annual Meeting.

MELVILLE, N.Y., May 13, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to announce that preliminary 26-, 52- and 104-week blinded preliminary data from the first 15 patients with chronic lumbar disc disease (“cLDD”) enrolled in the ongoing Phase 2 clinical trial of BRTX-100 was recently presented by Francisco Silva, Vice President of Research and Development, at the International Society for Cell & Gene Therapy (“ISCT”) 2025 Annual Meeting.

NEW YORK, NY / ACCESS Newswire / May 13, 2025 / If you suffered a loss on your Compass Group Diversified Holdings, LLC (NYSE:CODI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/compass-diversified-lawsuit-submission-form?prid=148251&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / May 13, 2025 / If you suffered a loss on your TFI International Inc. (NYSE:TFII) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/tfi-international-inc-lawsuit-submission-form?prid=148260&wire=1 or contact Joseph E. Levi, Esq.

Building on reputation for unparalleled performance, latest software delivers even greater accuracy, with 30% improvement in structural variant calling New features include easy-to-use oncology apps, enhanced multiomics pipelines, and AWS F2 support enabling faster turnaround times SAN DIEGO , May 13, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today announced the launch of DRAGEN™ version 4.4 software (v4.4), the industry's most comprehensive secondary analysis solution. The latest version of DRAGEN includes out-of-the-box oncology applications for clinical research and support for newly announced Illumina multiomics assays.

Apple is planning to launch its own thinner iPhone this fall according to The Wall Street Journal but Samsung has already unveiled its ultra-slim model.